ETV1 Drives CD4 + T Cell‐Mediated Intestinal Inflammation in Inflammatory Bowel Disease Through Amino Acid Transporter Slc7a5
Advanced Science · 2025
DOI: 10.1002/advs.202511595 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yan Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Digestive Endoscopic Center, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Inflammatory Bowel Diseases, DNA-Binding Proteins, Transcription Factors. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Shanghai Sailing Program.
Abstract (Originalsprache)
Excessive CD4 + T cell responses drive inflammatory bowel disease (IBD), yet the transcriptional mechanisms underlying their dysfunction remain incompletely understood. Here, it is demonstrated that E‐twenty‐six variant transcription factor 1 (ETV1) is upregulated in IBD patients and positively correlates with disease severity. Etv1 deficiency impairs CD4 + T cell activation, proliferation, and T helper 17 (Th17) cell differentiation, thereby ameliorating TNBS‐induced colitis. Moreover, Etv1 deficiency attenuates CD45RB high CD4 + T cell‐induced colitis, characterized by a reduction in pathogenic CD4 + T cells in the intestinal mucosa. Pharmacological inhibition of ETV1 ameliorates colitis in recombination activating gene 1‐deficient mice and suppresses human IBD T cell responses ex vivo. Mechanistically, Etv1 binds to the promoter of the gene encoding the amino acid transporter solute carrier family 7 member 5 (Slc7a5), enhancing its expression and subsequent amino acid uptake to fuel T cell pathogenicity. Restoring Slc7a5 expression rescues the proliferation, differentiation, and colitogenic function of Etv1‐deficient CD4⁺ T cells. Clinically, SLC7A5 is upregulated in IBD, and its blockade ameliorates T cell‐driven colitis in vivo. Collectively, the results establish a critical role for the ETV1‐Slc7a5 axis in driving pathogenic CD4⁺ T cell responses in IBD, highlighting this pathway as a novel therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Digestive Endoscopic Center, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
- Department of Gastroenterology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
- Department of Gastroenterology, The Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, 200072, China.
ORCID-Profile: Yan Shi
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
- Shanghai Sailing Program
- Shanghai Municipal Health Commission
- Natural Science Foundation of Shanghai Municipality
Zitieren
APA
Shi, Y., Wang, S., Yan, Y., Chen, W., Cao, Y., Chen, D., Chen, W., Ma, C., & Wan, X. (2025). ETV1 Drives CD4 + T Cell‐Mediated Intestinal Inflammation in Inflammatory Bowel Disease Through Amino Acid Transporter Slc7a5. Advanced Science. https://doi.org/10.1002/advs.202511595
Vancouver
Shi Y, Wang S, Yan Y, Chen W, Cao Y, Chen D, et al. ETV1 Drives CD4 + T Cell‐Mediated Intestinal Inflammation in Inflammatory Bowel Disease Through Amino Acid Transporter Slc7a5. Advanced Science. 2025. doi:10.1002/advs.202511595
BibTeX
@article{Shi2025,
author = {Shi, Yan and Wang, Song and Yan, Yuqing and Chen, Wei and Cao, Yingying and Chen, Dafan and Chen, Wei and Ma, Caiyun and Wan, Xinjian},
title = {ETV1 Drives CD4 + T Cell‐Mediated Intestinal Inflammation in Inflammatory Bowel Disease Through Amino Acid Transporter Slc7a5},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202511595}
}
EUVIMED